


09/09/2010

Listing of Claims:

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

1. – 2. (Cancelled)


3. (Currently Amended) A compound of formula (I) according to claim 2

the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein






n is 0; X is N or CR⁵, wherein R⁵ is hydrogen; R¹ is C₁₋₆alkyl;

R² is hydrogen or hydroxy or taken together with R⁴ may form =O; R³ is -(CH₂)_s-NR⁶R⁷;

s is 0 or 1; R⁶ is -CHO or C₁₋₆alkyl; R⁷ is hydrogen or C₁₋₆alkyl;

~~and~~ R⁴ is hydrogen, C₁₋₆alkyl -or- .


4. (Currently Amended) A compound selected from the group consisting of:

 <p style="text-align: right;">compound 1</p>	 <p style="text-align: right;">compound 5</p>
 <p style="text-align: right;">compound 7</p>	 <p style="text-align: right;">compound 3</p>
 <p style="text-align: right;">compound 17</p>	


and the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof.

5. – 12. (Cancelled)


13. (Currently Amended) A process for preparing a compound as claimed in claim 23, comprising: a) hydrolysis of intermediates of formula (VIII),



b) cyclization of intermediates of formula (X),



or c) condensation of an ortho-benzenediamine of formula (XI) with an ester of formula (XII) wherein R^h is C₁₋₆alkyl, into compounds of formula (I), wherein X is N, herein referred to as compounds of formula (I-i),



14. (Cancelled)

15. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 3.

16. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 4.


17. - 26. (Cancelled)

27. (Previously Presented) A combination of a compound with a cancer treating chemotherapeutic agent wherein said compound is a compound of claim 3.

28. (Previously Presented) A combination of a compound with a cancer treating chemotherapeutic agent wherein said compound is a compound of claim 4.

29. - 30. (Cancelled)

31. (Previously Presented) A compound selected from



and the *N*-oxide forms and the pharmaceutically acceptable addition salts thereof.

32. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 31.

33. (Previously Presented) A combination of a compound with a chemotherapeutic agent wherein said compound is a compound of claim 31.